A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer

Aflibercept, a recombinant fusion protein, is a potent inhibitor of vascular endothelial growth factor (VEGF)-A, VEGF-B, and the placental growth factor (PlGF). The present study was an open-label, sequential-cohort, dose-escalation trial of intravenous aflibercept administered every 2 weeks in comb...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Yoshino, Takayuki, Yamazaki, Kentaro, Yamaguchi, Kensei, Doi, Toshihiko, Boku, Narikazu, Machida, Nozomu, Onozawa, Yusuke, Asayama, Masako, Fujino, Tadahiro, Ohtsu, Atsushi
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2012
Teme:
Phase I Studies
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3717157/
https://ncbi.nlm.nih.gov/pubmed/23179335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9895-6
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items